Jamieson Wellness Inc. Announces Filing of Management Information Circular for Annual Meeting of Shareholders

Jamieson Wellness Inc. (" Jamieson Wellness " or the " Company ") (TSX: JWEL) announced today that the Company has filed its management information circular (" Circular ") and related materials (together with the Circular, the " Meeting Materials ") for the annual meeting of shareholders (the " Shareholders ") of Jamieson Wellness to be held on May 24, 2022 at 2:00 p.m. (Eastern Daylight Time) virtually via live audio webcast at meetnow.globalMZ4D4RR (the " Meeting ").

The Meeting Materials have been filed under Jamieson's profile on SEDAR at www.sedar.com and are also available on the Company's website at www.jamiesonwellness.com .

The Meeting Materials are being mailed to Shareholders to provide information about the business to be conducted at the Meeting, detailed instructions about how to vote shares and how to attend and participate at the Meeting. The Company encourages Shareholders to review the Meeting Materials before voting their shares.

Similar to last year, to proactively address the public health impact of the COVID-19 outbreak, to mitigate the risks to the health and safety of our communities, Shareholders, employees and other stakeholders, and to comply with any applicable public health restrictions limiting indoor events that may be in effect at the time of the Meeting, the Meeting will be held in a virtual only format.

About Jamieson Wellness

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. The Company also offers a variety of natural health solutions through its Progressive, Smart Solutions, Iron Vegan and Precision brands. For more information please visit jamiesonwellness.com .

Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

Contact

For questions or assistance with the completion and delivery of proxy materials, please contact Jamieson Wellness' proxy solicitation agent and shareholder communications advisor:

Laurel Hill Advisory Group
1.877.452.7184 toll-free in Canada
+1.416.304.0211 International
assistance@laurelhill.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

JWEL:CA
The Conversation (0)
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications... Keep Reading...
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue SystemsInMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the... Keep Reading...
SVN-114 selected as the lead candidate for PTSD discovery programme

SVN-114 selected as the lead candidate for PTSD discovery programme

Novel compound from patent-pending SVN-SDN-14 series targeting a major global mental health disorder

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery... Keep Reading...
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... Keep Reading...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned... Keep Reading...
Box of Moderna COVID-19 vaccine vials with red caps and labels.

Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims... Keep Reading...

Interactive Chart

Latest Press Releases

Related News